NeuroMetrix, Inc. To Present at the UBS Global Life Sciences Conference on Monday, September 26, 2005
Posted on: Thursday, 22 September 2005, 15:00 CDT
NeuroMetrix, Inc. (NASDAQ: NURO), a medical device company focused on the development and sale of proprietary products used to diagnose neuropathies, announced today that it is scheduled to present at the UBS Global Life Sciences Conference at the Grand Hyatt Hotel in New York City at 8:30 a.m. (Eastern Time) on Monday, September 26, 2005. The audio presentation will be simultaneously available via webcast on the "Investors" home page at http://www.neurometrix.com.
Brad Smith, NeuroMetrix Chief Financial Officer, will be presenting at the conference. Mr. Smith will provide an overview of NeuroMetrix and will provide an update on operational and strategic matters relating to the business.
About NeuroMetrix
NeuroMetrix is a medical device company that is establishing a new standard of care through the design, development and sale of proprietary products used to diagnose neuropathies. Neuropathies are diseases of the peripheral nerves and parts of the spine that frequently are caused by or associated with diabetes, low back pain and carpal tunnel syndrome, as well as other clinical disorders. The NC-stat System, the Company's neuropathy diagnostic system, has been on the market since May 1999 and is presently used in nearly 2,700 physician's offices, clinics and other health care facilities in the United States. The Company holds issued utility patents covering a number of important aspects of the NC-stat System.
Source: Business Wire
Related Articles
- NeuroMetrix Completes CE Technical File and Achieves CE Marking for Its ADVANCE(TM) System Allowing Marketing in the European Union
- NeuroMetrix Announces Initial Sales of ADVANCE(TM) System for the Performance of Nerve Conduction Studies and Needle Electromyography Procedures to Neurologists and Other Specialists
- NeuroMetrix Receives FDA 510(K) Clearance for the ADVANCE(TM) System for the Performance of Nerve Conduction Studies and Needle Electromyography Procedures
- NeuroMetrix Says Securities Class Action Lawsuit Without Merit
- NeuroMetrix Inc. Highlights Recent Publication of Peer-Reviewed Journal Articles Related to NC-Stat System
- NeuroMetrix, Inc. Notes Publication of Study Validating NC-Stat System for Detection of Diabetic Polyneuropathy
- NeuroMetrix, Inc. Announces Latest FDA 510(K) Clearance for NC-Stat System
- Pulsed Infrared Light Therapy System Used in Published Study on Diabetic Peripheral Neuropathy in the May 2006 Issue of Acta Diabetologica
- The Quigley Corporation Reports First Quarter Results; Continues Its Investing for the Future in Pharmaceutical R&D
- NeuroMetrix Announces Physician Use of One Millionth NC-Stat Nerve Conduction Study Biosensor
 |
 |
User Comments (0)
RSS Feeds